Combined alpelisib and fulvestrant showed better median PFS of 11 months compared to 5.7 months in the placebo-fulvestrant group (HR 0.65, 95% CI 0.5–0.85; p = 0.001) in patients with PIK3CA-mutated cancer [84] (refer to Table 2). The gene discussed is PIK3CA; the disease is cancer.